SCHEMBL29640824

SCHEMBL29640824

Cc1cn(-c2ccc(N)nc2)nn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.44
LRRK2 Q5S007 1/20 0.44
NOS3 P29474 1/20 0.42
NOS2 P35228 1/20 0.42
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
RXRA P19793 7/20 0.36
GRIN1 Q05586 7/20 0.36
GRIN2B Q13224 7/20 0.36
BRD4 O60885 1/20 0.36
NOTUM Q6P988 3/20 0.36
FLT3 P36888 2/20 0.36
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
EP300 Q09472 1/20 0.34
EGLN2 Q96KS0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21275488 1.00 MAPT (0.44) MAPTLRRK2NOS3NOS2CA12
SCHEMBL23999583 0.84 DDX3X (0.41) LRRK2RXRAGRIN1GRIN2BBRD4
SCHEMBL12369740 0.79 RXRA (0.45) MAPTRXRAGRIN1GRIN2BNOTUM
SCHEMBL3753945 0.78 ESRRA (0.47) LRRK2CA12CA1CA2CA9
SCHEMBL12396055 0.76 JAK2 (0.52) MAPTCA12CA1CA2CA9
SCHEMBL30979817 0.76 NOTUM (0.43) LRRK2RXRAGRIN1GRIN2BNOTUM
SCHEMBL30343244 0.76 GRIN1 (0.38) LRRK2RXRAGRIN1GRIN2BNOTUM
SCHEMBL25043775 0.76 GRIN1 (0.38) LRRK2RXRAGRIN1GRIN2BNOTUM
SCHEMBL13183572 0.74 NOTUM (0.59) MAPTLRRK2CA12CA1CA2
SCHEMBL3340257 0.72 KDM4E (0.49) MAPTLRRK2RXRAGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230137-A1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2025-07-17 US disclosed
EP-3752497-B1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
CN-112218857-B P300/CBP HAT inhibitors and methods of use thereof 星座制药公司 2023-11-21 CN disclosed
US-20220331304-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS CONSTELLATION PHARMACEUTICALS, INC. 2022-10-20 US disclosed
EP-4003342-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS Constellation Pharmaceuticals, Inc. (US) 2022-06-01 EP disclosed
CN-114450005-A Compounds for the treatment of neurological disorders 星座制药公司 2022-05-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331304-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS CLN6, ACHE, NLN MAPT 22/4885LRRK2 1488/4885NOS3 2159/4885
US-20250230137-A1 P300/CBP HAT INHIBITORS EP300, HDAC1, KAT2A MAPT 887/4885LRRK2 909/4885NOS3 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.